CTOs on the Move

Rain Therapeutics

www.rainthera.com

 
Rain Therapeutics is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.rainthera.com
  • 8000 Jarvis Avenue Suite 204
    Newark, CA USA 94560
  • Phone: 510.953.5559

Executives

Name Title Contact Details

Funding

Rain Therapeutics raised $18.4M on 05/21/2018
Rain Therapeutics raised $63M on 09/03/2020

Similar Companies

Brii Biosciences

Brii Biosciences (Brii Bio) is a company committed to serving patients` needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world`s second largest pharmaceutical market. The company`s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People`s Republic of China and the United States, with offices in Shanghai, Beijing, San Francisco, and Durham, North Carolina.

ALX Oncology

ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

ITOCHU Chemicals America

ITOCHU Chemicals America is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.